1. Li, Z., et al., Genetic mutations associated with metastatic clear cell renal cell carcinoma. Oncotarget, 2016.
2. Nilsson, H., et al., Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate. Cell Death Dis, 2015. 6: p. e1585.
3. Wrzesinski, T., et al., Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors. BMC Cancer, 2015. 15: p. 518.
4. Society, A.C., Kidney Cancer (Adult) - Renal Cell. 2014, American Cancer Society.
5. Zhang, L., et al., Growth Pattern of Clear Cell Renal Cell Carcinoma in Patients with Delayed Surgical Intervention: Fast Growth Rate Correlates with High Grade and May Result in Poor Prognosis. Biomed Res Int, 2015. 2015: p. 598134.
6. Pinthus, J.H., et al., Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications. Can Urol Assoc J, 2011. 5(4): p. 274-82.
7. Tun, H.W., et al., Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One, 2010. 5(5): p. e10696.
8. Copland JA, M.J., Wu K, Cernigliaro JG and Tan WW, A Patient with Metastatic Clear Cell Renal Carcinoma. Ann Hematol Oncol, 2014. 1(2): p. 1007.
9. Myszczyszyn, A., et al., The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Rev, 2015. 11(6): p. 919-43.
10. Pattabiraman, D.R. and R.A. Weinberg, Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov, 2014. 13(7): p. 497-512.
11. Bussolati, B., et al., Human renal cancer stem cells. Cancer Lett, 2013. 338(1): p. 141-6.
12. Lenburg, M.E., et al., Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer, 2003. 3: p. 31.
13. Pritchett, T.L., et al., Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney. Oncogene, 2015. 34(20): p. 2631-9.
14. Hsu, T., Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms. Oncogene, 2012. 31(18): p. 2247-57.
15. Gossage, L., T. Eisen, and E.R. Maher, VHL, the story of a tumour suppressor gene. Nat Rev Cancer, 2015. 15(1): p. 55-64.
16. Haase, V.H., The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int, 2006. 69(8): p. 1302-7.
17. Dallmeier, D., et al., Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study. Diabetol Metab Syndr, 2012. 4(1): p. 28.
18. Kalantar-Zadeh, K., Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol, 2007. 2(5): p. 872-5.
19. Stengel, B., Chronic kidney disease and cancer: a troubling connection. J Nephrol, 2010. 23(3): p. 253-62.
20. Rea, D., et al., Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer, 2015. 112(9): p. 1613-5.
21. Klampfer, L., Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets, 2011. 11(4): p. 451-64.
22. Bishayee, A., The role of inflammation and liver cancer. Adv Exp Med Biol, 2014. 816: p. 401-35.
23. Chen, C. and G. Wang, Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol, 2015. 7(15): p. 1964-70.
24. Cohen, E.N., et al., Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS One, 2015. 10(7): p. e0132710.
25. Singh, A. and J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 2010. 29(34): p. 4741-51.
26. de Vivar Chevez, A.R., J. Finke, and R. Bukowski, The role of inflammation in kidney cancer. Adv Exp Med Biol, 2014. 816: p. 197-234.
27. Tan, W., et al., Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J Urol, 2011. 186(5): p. 2071-7.
28. Pena-Llopis, S., et al., BAP1 loss defines a new class of renal cell carcinoma. Nat Genet, 2012. 44(7): p. 751-9.
29. Kily, L.J., et al., Gene expression changes in a zebrafish model of drug dependency suggest conservation of neuro-adaptation pathways. J Exp Biol, 2008. 211(Pt 10): p. 1623-34.
30. Miller, W.R., et al., Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics, 2007. 17(10): p. 813-26.
31. Manalo, D.J., et al., Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood, 2005. 105(2): p. 659-69.
32. Nakagawa, S., et al., Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease. PLoS One, 2015. 10(8): p. e0136994.
33. Prinsen, B.H., et al., Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int, 2003. 64(4): p. 1495-504.
34. Cook, H.T., Complement and kidney disease. Curr Opin Nephrol Hypertens, 2013. 22(3): p. 295-301.
35. Jatiani, S.S., et al., Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer, 2010. 1(10): p. 979-93.
36. Harrison, D.A., The Jak/STAT pathway. Cold Spring Harb Perspect Biol, 2012. 4(3).
37. Carina, V., et al., Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2. Thyroid, 2013. 23(7): p. 829-37.
38. Sudarshan, S., et al., Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol, 2013. 63(2): p. 244-51.
39. Sorensen-Zender, I., et al., Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease. BMC Nephrol, 2013. 14: p. 145.
40. Leduc, M.S., et al., Comprehensive evaluation of apolipoprotein H gene (APOH) variation identifies novel associations with measures of lipid metabolism in GENOA. J Lipid Res, 2008. 49(12): p. 2648-56.
41. Dang, C.V., Links between metabolism and cancer. Genes Dev, 2012. 26(9): p. 877-90.
42. Zaromytidou, A.-I., Intestinal tumour initiation by dedifferentiation. Nat Cell Biol, 2013. 15(3): p. 240-240.
43. Lim, S. and P. Kaldis, Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development, 2013. 140(15): p. 3079-93.
44. Deb-Basu, D., et al., MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2. Cell Cycle, 2006. 5(12): p. 1348-55.
45. Ando, K., F. Ajchenbaum-Cymbalista, and J.D. Griffin, Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A, 1993. 90(20): p. 9571-5.
46. Zhang, Y.M., et al., Endothelin-1 promoted proliferation of vascular smooth muscle cell through pathway of extracellular signal-regulated kinase and cyclin D1. Acta Pharmacol Sin, 2003. 24(6): p. 563-8.
47. Takeda, D.Y. and A. Dutta, DNA replication and progression through S phase. Oncogene, 2005. 24(17): p. 2827-43.
48. Masuda, T., S. Mimura, and H. Takisawa, CDK- and Cdc45-dependent priming of the MCM complex on chromatin during S-phase in Xenopus egg extracts: possible activation of MCM helicase by association with Cdc45. Genes Cells, 2003. 8(2): p. 145-61.
49. Alao, J.P., The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer, 2007. 6: p. 24.
50. Wang, D., et al., The expression of glyceraldehyde-3-phosphate dehydrogenase associated cell cycle (GACC) genes correlates with cancer stage and poor survival in patients with solid tumors. PLoS One, 2013. 8(4): p. e61262.
51. Kramer, E.R., et al., Mitotic regulation of the APC activator proteins CDC20 and CDH1. Mol Biol Cell, 2000. 11(5): p. 1555-69.
52. Melkerson-Watson, L.J., et al., Elevation of lymphocyte CD45 protein tyrosine phosphatase activity during mitosis. J Immunol, 1994. 153(5): p. 2004-13.
53. Sharma, A., K. Singh, and A. Almasan, Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol, 2012. 920: p. 613-26.
54. Kuo, L.J. and L.X. Yang, Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo, 2008. 22(3): p. 305-9.
55. Coussens, L.M. and Z. Werb, Inflammation and cancer. Nature, 2002. 420(6917): p. 860-7.
56. Forster, R., L. Ohl, and G. Henning, Lessons learned from lymphocytes: CC chemokine receptor-7 involved in lymphogenic metastasis of melanoma. J Natl Cancer Inst, 2001. 93(21): p. 1588-9.
57. Lim, S.Y., et al., Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells. Oncogene, 2016.
58. Gouwy, M., et al., CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection. Eur J Immunol, 2011. 41(4): p. 963-73.
59. Nombela-Arrieta, C., et al., Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. Immunity, 2004. 21(3): p. 429-41.
60. Fukui, Y., et al., Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature, 2001. 412(6849): p. 826-31.
61. Park, S.H., et al., Spin90 deficiency increases CXCL13-mediated B cell migration. Scand J Immunol, 2014. 80(3): p. 191-7.
62. Hui, W., C. Zhao, and S.G. Bourgoin, LPA Promotes T Cell Recruitment through Synthesis of CXCL13. Mediators Inflamm, 2015. 2015: p. 248492.
63. Sakofsky, C.J., S. Ayyar, and A. Malkova, Break-induced replication and genome stability. Biomolecules, 2012. 2(4): p. 483-504.
64. Cullen, R., et al., Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. J Immunol, 2009. 183(9): p. 5807-15.
65. Gavala, M.L., et al., Nucleotide receptor P2RX7 stimulation enhances LPS-induced interferon-beta production in murine macrophages. J Leukoc Biol, 2013. 94(4): p. 759-68.
66. You, Y., et al., Latexin sensitizes leukemogenic cells to gamma-irradiation-induced cell-cycle arrest and cell death through Rps3 pathway. Cell Death Dis, 2014. 5: p. e1493.
67. Li, Y., X. Wen, and Y. Liu, Tubular cell dedifferentiation and peritubular inflammation are coupled by the transcription regulator Id1 in renal fibrogenesis. Kidney Int, 2012. 81(9): p. 880-91.
68. Deng, W., et al., MicroRNA Replacing Oncogenic Klf4 and c-Myc for Generating iPS Cells via Cationized Pleurotus eryngii Polysaccharide-based Nanotransfection. ACS Appl Mater Interfaces, 2015. 7(34): p. 18957-66.
69. Ai, Z., et al., Maintenance of Self-Renewal and Pluripotency in J1 Mouse Embryonic Stem Cells through Regulating Transcription Factor and MicroRNA Expression Induced by PD0325901. Stem Cells Int, 2016. 2016: p. 1792573.
70. Ohtsuka, S. and H. Niwa, The differential activation of intracellular signaling pathways confers the permissiveness of embryonic stem cell derivation from different mouse strains. Development, 2015. 142(3): p. 431-7.
71. Rosano, L., F. Spinella, and A. Bagnato, Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer, 2013. 13(9): p. 637-51.
72. Kim, T.H., et al., beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene, 2005. 24(4): p. 597-604.
73. Schnoor, M., et al., Crossing the Vascular Wall: Common and Unique Mechanisms Exploited by Different Leukocyte Subsets during Extravasation. Mediators Inflamm, 2015. 2015: p. 946509.
74. Young, S.A., et al., Integrin alpha4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma. PLoS One, 2015. 10(5): p. e0120815.
75. Goodridge, H.S., D.M. Underhill, and N. Touret, Mechanisms of Fc receptor and dectin-1 activation for phagocytosis. Traffic, 2012. 13(8): p. 1062-71.
76. Shivtiel, S., et al., CD45 regulates retention, motility, and numbers of hematopoietic progenitors, and affects osteoclast remodeling of metaphyseal trabecules. J Exp Med, 2008. 205(10): p. 2381-95.
77. He, Z., et al., Expression of Col1a1, Col1a2 and procollagen I in germ cells of immature and adult mouse testis. Reproduction, 2005. 130(3): p. 333-41.
78. Czaja, A.J., Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol, 2014. 20(10): p. 2515-32.
79. Meng, H., et al., DCDC2 is associated with reading disability and modulates neuronal development in the brain. Proc Natl Acad Sci U S A, 2005. 102(47): p. 17053-8.
80. D′Asti, E., et al., Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factor-thrombin cross-talk. J Thromb Haemost, 2014. 12(11): p. 1838-49.
81. Kushner, J.A., et al., Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol, 2005. 25(9): p. 3752-62.
82. Koyama-Nasu, R., et al., The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells. Oncogene, 2013. 32(33): p. 3840-5.
83. Sinadinos, A., et al., P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy. PLoS Med, 2015. 12(10): p. e1001888.
84. Swafford, A.D., et al., An allele of IKZF1 (Ikaros) conferring susceptibility to childhood acute lymphoblastic leukemia protects against type 1 diabetes. Diabetes, 2011. 60(3): p. 1041-4.
85. Virely, C., et al., Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia, 2010. 24(6): p. 1200-4.
86. Raj, T., et al., Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 2006. 26(8): p. 1845-51.
87. Velasco-Velazquez, M., et al., CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res, 2012. 72(15): p. 3839-50.
88. Panse, J., et al., Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer, 2008. 99(6): p. 930-8.
89. Tanaka, T., et al., Chemokines in tumor progression and metastasis. Cancer Sci, 2005. 96(6): p. 317-22.
90. Hiraga, T., S. Ito, and H. Nakamura, Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res, 2013. 73(13): p. 4112-22.
91. Wu, C.-I., et al., Impacts of protease inhibitors on clathrin and fibronectin in cancer metastasis. Biomarkers and Genomic Medicine, 2014. 6(1): p. 23-31.
92. Salama, R.H.M., et al., Midkine, a heparin-binding growth factor, produced by the host enhances metastasis of Lewis lung carcinoma cells. Cancer Letters, 2006. 233(1): p. 16-20.